SBFM Company Profile and Key Details
NASDAQ : SBFM
Sunshine Biopharma
$1.05
0.02+1.94%
At Close 4:00 PM$0.87
−0.18-17.17%
Pre-Market 07:44 AM62.29
B-ESG ScoreESG Rating
Price Chart
Stock Price Today
Sunshine Biopharma, Inc. (SBFM) stock surged +1.94%, trading at $1.05 on NASDAQ, up from the previous close of $1.03. The stock opened at $1.03, fluctuating between $1.01 and $1.07 in the recent session.
Stock Snapshot
1.03
Prev. Close
5.15M
Market Cap
1.01
Day Low
-0.73
P/E Ratio
-1.44
EPS (TTM)
-0.4
Cash Flow per Share
1.03
Open
4.91M
Number of Shares
1.07
Day High
99.96%
Free Float in %
0.89
Book Value
178.15K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 12, 2026 | 1.03 | 1.07 | 1.01 | 1.05 | 235.7K |
| May 11, 2026 | 1.04 | 1.14 | 1.02 | 1.03 | 131.58K |
| May 08, 2026 | 1.08 | 1.09 | 1.03 | 1.05 | 28.13K |
| May 07, 2026 | 1.09 | 1.09 | 1.07 | 1.08 | 16.71K |
| May 06, 2026 | 1.00 | 1.09 | 1.00 | 1.08 | 33.91K |
| May 05, 2026 | 1.11 | 1.11 | 1.03 | 1.05 | 39.73K |
| May 04, 2026 | 1.06 | 1.10 | 1.06 | 1.10 | 24.21K |
| Apr 30, 2026 | 0.95 | 0.96 | 0.95 | 0.96 | 30.42K |
| Apr 29, 2026 | 0.97 | 0.98 | 0.95 | 0.97 | 15.33K |
| Apr 28, 2026 | 0.98 | 0.98 | 0.96 | 0.98 | 27.6K |
| Apr 27, 2026 | 1.00 | 1.00 | 0.97 | 0.98 | 36.43K |
| Apr 23, 2026 | 0.99 | 1.00 | 0.98 | 0.99 | 8.77K |
| Apr 22, 2026 | 0.99 | 1.00 | 0.98 | 0.99 | 44.75K |
| Apr 21, 2026 | 1.02 | 1.02 | 0.99 | 1.00 | 40.72K |
| Apr 20, 2026 | 1.03 | 1.03 | 1.01 | 1.02 | 14.33K |
| Apr 17, 2026 | 1.02 | 1.04 | 1.01 | 1.03 | 31.15K |
| Apr 16, 2026 | 1.00 | 1.01 | 0.98 | 1.01 | 17.27K |
| Apr 14, 2026 | 0.99 | 1.02 | 0.95 | 0.97 | 11.57K |
| Apr 13, 2026 | 1.00 | 1.02 | 0.98 | 0.99 | 18.14K |
| Apr 10, 2026 | 1.04 | 1.04 | 0.95 | 1.00 | 98.39K |
Contact Details
About Company
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Company Information
| Employees | 52 |
| Beta | 1.64 |
| Sales or Revenue | $24.09M |
| 5Y Sales Change% | 66.466% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Stock Peers
NBIX
5.21+3.46%
Neurocrine Biosciences, Inc.$155.80ITCI00
Intra-Cellular Therapies, Inc.$131.87LNTH2.16+2.30%
Lantheus Holdings, Inc.$96.23ANIP0.79+1.00%
ANI Pharmaceuticals, Inc.$79.50SUPN1.16+2.35%
Supernus Pharmaceuticals, Inc.$50.53INDV-0.56-1.44%
Indivior Pharmaceuticals Inc$38.28PAHC0.26+0.72%
Phibro Animal Health Corporation$36.58COLL-0.12-0.34%
Collegium Pharmaceutical, Inc.$35.69PETQ-0.01-0.03%
PetIQ, Inc.$30.98HROW-9.01-23.69%
Harrow Health, Inc.$29.03Technical Performance
Short-term trend indicators are bullishly aligned (SMA20 3.27%, SMA50 -1.83%, SMA200 -16.03%). The stock’s 14-day RSI is 53.25 (neutral), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -68.46% below its high and over 8.85% above its low. Average 10-day trading volume of 72.85 thousand shares is significantly above the 3-month average of 38.67 thousand, indicating heightened recent market interest.
Dividend & Fair Value
Sunshine Biopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.08. This means the shares are trading near this model’s fair value.
Earnings & Analyst Outlook
Sunshine Biopharma, Inc. generated EPS of -$1.86 over the past year. Five-year average earnings growth is 82.07%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $7.00. The high target offers 566.67% upside. The low target suggests 566.67% downside. The mean target is $7.00. This offers 566.67% upside. Sunshine Biopharma, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 04, 2026, missed forecasts by 187.5%. The prior quarter beat by 11.11%. Over the last six quarters, Apple has recorded several small beats. These include 34.32% in August 16, 2024.
Shareholding & Insider Activity
Sunshine Biopharma, Inc. has 4.56 million shares outstanding. The public float is 4.55 million shares, elevated short interest at 6.33% of float. This equals 288.27 thousand shares. The short ratio is 4.7 days. Institutional investors hold 5.25% of the float. Insiders own 0.04%.
Financial & Profitability Overview
On valuation metrics, Sunshine Biopharma trades at a P/E of -0.73, P/S of 0.14 and P/B of 0.19. The current ratio is 4.17 and quick ratio is 2.08. Operationally, the company’s inventory turnover is 1.79 and cash conversion cycle is 152.79 days. Debt-to-equity is 0.04, supported by a cash flow-to-debt ratio of -6.56.
Quarterly Financial Highlights
The company ended the quarter with $16.29M in cash and short-term investments, a total debt of $657.71K, and net debt of - $15.63M. Total assets were $27.35M, with equity of $21.21M. Financials further reflected weakness, with operating cash flow of - $8.78M, free cash flow of - $9.56M, and capital expenditures of - $788.10K.
Frequently Asked Questions
What is the current Sunshine Biopharma, Inc. (SBFM) stock price?
Sunshine Biopharma, Inc. (NASDAQ: SBFM) stock price is $1.05 in the last trading session. During the trading session, SBFM stock reached the peak price of $1.07 while $1.01 was the lowest point it dropped to. The percentage change in SBFM stock occurred in the recent session was 1.94% while the dollar amount for the price change in SBFM stock was $0.02.
SBFM's industry and sector of operation?
The NASDAQ listed SBFM is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Sunshine Biopharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of SBFM?
No Data
How SBFM did perform over past 52-week?
SBFM's closing price is 10.53% higher than its 52-week low of $0.95 where as its distance from 52-week high of $2.43 is -56.79%.
How many employees does SBFM have?
Number of SBFM employees currently stands at 52.
Link for SBFM official website?
Official Website of SBFM is: https://www.sunshinebiopharma.com
How do I contact SBFM?
SBFM could be contacted at phone 514 426 6161 and can also be accessed through its website. SBFM operates from 6500 Trans-Canada Highway, Pointe-Claire, QC H9R 0A5, Canada.
How many shares of SBFM are traded daily?
SBFM stock volume for the day was 178.15K shares. The average number of SBFM shares traded daily for last 3 months was 42.6K.
What is the market cap of SBFM currently?
The market value of SBFM currently stands at $5.15M with its latest stock price at $1.05 and 4.91M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep